| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (NCT04889430) | Novartis Pharmaceuticals | 2022-01-17 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (NCT04958265) | Hoffmann-La Roche | 2021-11-17 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (NCT04861259) | Hoffmann-La Roche | 2021-10-22 |
| Eculizumab to Cemdisiran Switch in aHUS (NCT03999840) | Mario Negri Institute for Pharmacological Research | 2021-01-01 |
| Observational Study of Elizaria® in aHUS Patients (NCT04749810) | AO GENERIUM | 2019-12-19 |
| Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients (NCT03518203) | Children's Hospital Medical Center, Cincinnati | 2018-08-03 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (NCT03205995) | Omeros Corporation | 2018-05-02 |
| Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series (NCT03574506) | Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia | 2018-04-15 |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome (NCT03303313) | Alnylam Pharmaceuticals | 2017-09-19 |
| The Role of Microparticles as a Biomarker (NCT02626663) | University of Rochester | 2016-07-01 |
| Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (NCT02614898) | Alexion Pharmaceuticals, Inc. | 2015-11-04 |
| Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS (NCT02574403) | Nantes University Hospital | 2015-11-01 |
| Complement Inhibition in aHUS Dialysis Patients (NCT02464891) | Mario Negri Institute for Pharmacological Research | 2015-06-04 |
| Atypical Hemolytic-Uremic Syndrome (aHUS) Registry (NCT01522183) | Alexion Pharmaceuticals, Inc. | 2013-03-18 |
| aHUS Observational Long Term Follow-Up (NCT01522170) | Alexion Pharmaceuticals, Inc. | 2012-03-01 |
| An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (NCT01193348) | Alexion Pharmaceuticals, Inc. | 2010-09-01 |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (NCT01793168) | Sanford Health | 2010-07-01 |
| An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome (NCT01194973) | Alexion Pharmaceuticals, Inc. | 2010-07-01 |
| National Registry of Rare Kidney Diseases (NCT06065852) | UK Kidney Association | 2009-11-06 |
| Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS (NCT00844428) | Alexion Pharmaceuticals, Inc. | 2009-07-01 |
| Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) (NCT00838513) | Alexion Pharmaceuticals, Inc. | 2009-07-01 |
| Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (NCT00844545) | Alexion Pharmaceuticals, Inc. | 2009-05-01 |
| Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (NCT00844844) | Alexion Pharmaceuticals, Inc. | 2009-05-01 |